{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"792","value":"2560"},{"comment":"Not calculable (n=1)","groupId":"OG001","spread":"NA","value":"2280"}]}],"title":"Day 1 Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"693","value":"3110"},{"comment":"Not calculable (n=1)","groupId":"OG001","spread":"NA","value":"2960"}]}],"title":"Day 3 Cycle 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"AUC0-inf of trilaciclib in plasma was determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received trilaciclib 200 mg/m\\^2 administered intravenously (IV) once daily on Days 1 to 3 of each 21-day E/P chemotherapy cycle.","id":"OG000","title":"Part 1: Cohort 1 Trilaciclib 200 mg/m^2"},{"description":"Participants received trilaciclib 240 mg/m\\^2 administered IV once daily on Days 1 to 3 of each 21-day E/P chemotherapy cycle.","id":"OG001","title":"Part 1: Cohort 2 Trilaciclib 240mg/m^2"}],"paramType":"MEAN","populationDescription":"PK analysis set - included all participants with evaluable PK profiles for both treatments and analytes","reportingStatus":"POSTED","timeFrame":"Days 1 and 3 of Cycle 1 for a 21-day cycle","title":"Area Under the Plasma Concentration Versus Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) for Trilaciclib in Cycle 1, Part 1","type":"SECONDARY","unitOfMeasure":"h*ng/mL"}